BLOOD PLASMA DERIVATIVES FOR IVD MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-198584 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Blood Plasma Derivatives for IVD Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET
7.1 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES FOR IVD MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Biotest AG
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 CSL Limited (Australia)
16.3 Kedrion SpA
16.4 Baxter International Inc
16.5 Grifols
16.6 Fusion Healthcare
16.7 Bain Capital LLC
16.8 SK Plasma
16.9 Octapharma AG
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeAlbumin
Anti-Thrombin III
Intravenous Immunoglobulin (IVIG)
Fresh Frozen Plasma (FFP)
Others
By Application
Infectious Disease
Diabetes
Oncology
Cardiology
Nephrology
Autoimmune Diseases
Drug Testing
Others
Companies
Biotest AG
CSL Limited (Australia)
Kedrion SpA
Baxter International Inc
Grifols
Fusion Healthcare
Bain Capital LLC
SK Plasma
Octapharma AG
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.